Figure 1.
Figure 1. Disease-free survival of patients treated with hyper-CVAD and imatinib mesylate compared with those treated with non-imatinib mesylate-containing hyper-CVAD and VAD regimens. Note: a long-term survivor at 15 years in the VAD group is not shown.

Disease-free survival of patients treated with hyper-CVAD and imatinib mesylate compared with those treated with non-imatinib mesylate-containing hyper-CVAD and VAD regimens. Note: a long-term survivor at 15 years in the VAD group is not shown.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal